Effect of Dimethyl Fumarate (DMF) on T-cell Acute Lymphoblastic Leukemia

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 30; no. 1; p. 1
• Main Authors: Xu, Jin-Ge, Cheng, Qiao, Zhang, Gui-Hua, Kong, Li-Ping, Li, Li, Liu, Kai-Ge, Wu, Jin-Yan, Zhang, Qiu-Rong
• Format: Journal Article
• Language: Chinese
• Published: China 01.02.2022
• Subjects: Dimethyl Fumarate - pharmacology; HEK293 Cells; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; T-Lymphocytes; Ubiquitin-Protein Ligases; nuclear factor-erythroid 2-related factor 2; dimethyl fumarate; HACE1; T-cell acute lymphoblastic leukemia
• ISSN: 1009-2137
• DOI: 10.19746/j.cnki.issn.1009-2137.2022.01.01

To explore the effect and possible mechanism of dimethyl fumarate (DMF) on T-cell acute lymphoblastic leukemia (T-ALL), and provide experimental and theoretical basis for the clinical treatment of T-ALL. Jurkat cells were treated with different concentrations of DMF for 24 hours, and then the proportion and absolute count of Ki67-positive Jurkat cells were analyzed by flow cytometry. Meanwhile, the protein levels of nuclear factor-erythroid 2-related factor 2 (Nrf2) and E3 ubiquitin ligase HACE1 in Jurkat cells treated with DMF for 24 hours were evaluated by Western blot. Nrf2 proteins were co-immunoprecipitated in Jurkat cells, and then HACE1 protein was assessed by Western blot. Plasmids of Flag-Nrf2 and different gradients of Flag-HACE1 were transfected into HEK293T cells, and the levels of Flag-Nrf2 were detected by Western blot after 48 hours. DMF could significantly inhibit the proportion and absolute count of Ki67-positive Jurkat cells, and DMF inhibited the proliferation of Jurkat cells in a dose-depe